Monopar Therapeutics
Close on Oct 19, 2026
- Market cap
- $610.53M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 12, 2026 | During market hours | – | $-0.62 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | During market hours | – | $-0.46 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 27, 2026 | During market hours | – | $-0.61 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | Before market open | – | $0.48 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | Before market open | – | $-0.35 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 13, 2025 | Before market open | – | $-0.38 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 31, 2025 | Before market open | – | $-2.23 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 8, 2024 | Before market open | – | $-0.37 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 9, 2024 | Before market open | – | $0.10 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | Before market open | – | $-0.10 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 28, 2024 | Before market open | – | $-0.12 | – |
Press releases
Announcements Monopar Therapeutics filed with the SEC
Monopar Therapeutics Reports Second Quarter 2026
Results of operations · EX-99.1 to Form 8-K
Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease
Regulation FD disclosure · EX-99.1 to Form 8-K
Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease
Regulation FD disclosure · EX-99.1 to Form 8-K
Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease
Regulation FD disclosure · EX-99.1 to Form 8-K
Monopar Therapeutics Reports First Quarter 2026
Results of operations · EX-99.1 to Form 8-K
Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · EX-99.2 to Form 8-K
Monopar Reports Fourth Quarter and Full-Year 2025
Results of operations · EX-99.1 to Form 8-K
Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer
Regulation FD disclosure · EX-99.1 to Form 8-K
Monopar Therapeutics Reports Third Quarter 2025
Results of operations · EX-99.1 to Form 8-K
Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting ® 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
Monopar Announces Journal of Hepatology Publishes Physicians ’ Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150 th American Neurological Association Annual Meeting
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.3 to Form 8-K
Regulation FD disclosure · EX-99.3 to Form 8-K
Monopar Therapeutics Reports Second Quarter 2025
Results of operations · EX-99.1 to Form 8-K
Monopar Therapeutics Reports First Quarter 2025
Results of operations · EX-99.1 to Form 8-K
Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
Monopar Reports Fourth Quarter and Full-Year 2024
Results of operations · EX-99.1 to Form 8-K
Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu
Regulation FD disclosure · EX-99.1 to Form 8-K
Monopar Therapeutics Reports Third Quarter 2024
Results of operations · EX-99.1 to Form 8-K
Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate
Material agreement · Acquisition or disposition completed · New financial obligation · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024
Regulation FD disclosure · EX-99.1 to Form 8-K
Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers
Regulation FD disclosure · EX-99.1 to Form 8-K
Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers
Regulation FD disclosure · EX-99.1 to Form 8-K
Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr
Regulation FD disclosure · EX-99.1 to Form 8-K
Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule
Regulation FD disclosure · EX-99.1 to Form 8-K
Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers
Regulation FD disclosure · EX-99.1 to Form 8-K
Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr
Regulation FD disclosure · EX-99.1 to Form 8-K
Monopar Therapeutics Reports Second Quarter 2024
Results of operations · Charter or bylaw amendment · Shareholder vote results · EX-99.1 to Form 8-K
Monopar Therapeutics Announces 1-for-5 Reverse Stock Split
Results of operations · Charter or bylaw amendment · Shareholder vote results · EX-99.2 to Form 8-K
Monopar Announces First Patient Enrolled in First-in-Human Phase 1 Trial for Its Novel Radiopharmaceutical MNPR-101-Zr
Regulation FD disclosure · EX-99.1 to Form 8-K
Monopar and NorthStar Amend & Extend Collaboration
Regulation FD disclosure · EX-99.1 to Form 8-K
Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target
Regulation FD disclosure · EX-99.1 to Form 8-K
Ms. Tsuchimoto will be transitioning over the next month, with her last day being on June 30, 2024. Ms. Tsuchimoto will remain as a member of Monopar’s Board of Directors.
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Monopar Therapeutics Reports First Quarter 2024
Results of operations · EX-99.1 to Form 8-K